Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where T. Okamoto is active.

Publication


Featured researches published by T. Okamoto.


European Urology Supplements | 2014

243 Glycan modification of podoplanin enhances growth factor production through stabilization of platelet aggregation in bladder cancer cell

Y. Tobisawa; T. Okamoto; S. Hatakeyama; T. Yoneyama; Takuya Koie; Chikara Ohyama

INTRODUCTION AND OBJECTIVES: Non-muscle invasive bladder cancer is often treated by intravesical chemotherapy following transurethral resection. Mechanism of the effect of intravesical chemotherapy has yet to be elucidated. In this study, we investigated cell death mechanism induced by high-dose chemotherapeutics using a newly-developed culture method for primary cancer cells. METHODS: We have developed a novel culture method which enables preparation and culture of primary cancer cells as multicellular spheroids which are termed cancer tissue-originated spheroids (CTOSs) (Okuyama 2013 J Urol). First we generated a bladder cancer patient-derived xenograft. We prepared CTOSs from the xenograft, and exposed to high-dose (1mg/ml) of epirubicin (e-ADM) or mitomycin C (MMC) for 2 hours, or low-dose (0.01mg/ml) of those chemotherapeutics. We investigated absorption of chemotherapeutics into CTOSs and assessed the mode of cell death. Next, we prepared CTOSs directly from surgical specimens of bladder cancer and tested the individual responses after exposure to high-dose e-ADM and MMC. RESULTS: At high dose, e-ADM was promptly and homogenously delivered into cancer cells in the CTOSs. High-dose e-ADM and MMC decreased ATP levels in CTOSs within an hour accompanied with mitochondrial swelling and reduction of mitochondrial membrane potential, while plasma membrane integrity was maintained. Some of the molecules in mitochondrial apoptotic pathway were subsequently activated, while at later time point the cells lost integrity of cell membrane without DNA laddering. In contrast, CTOSs exposed to low-dose of eADM or MMC exhibited typical DNA laddering. Intriguingly, the decrease of ATP levels was varied among CTOSs derived from 20 surgical specimens. CONCLUSIONS: High-dose chemotherapeutics used in intravesical therapy may induce necrosis-like cell death, different from typical apoptosis caused by chemotherapeutics at the dose of systemic chemotherapy. Each bladder cancer may have a different response to high-dose chemotherapeutics used in intravesical therapy, indicating necessity of chemosensitivity test aiming for personalized medicine.


European Urology Supplements | 2016

333 Slow gait speed and rapid renal function decline are risk factors for postoperative delirium after urological surgery

S. Hatakeyama; T. Sato; T. Okamoto; Shogo Hosogoe; Hayato Yamamoto; Y. Tobisawa; T. Yoneyama; Takuya Koie; Chikara Ohyama


European Urology Supplements | 2015

657 Slow gait speed predict of post-operative delirium in elderly patients

Masaaki Oikawa; S. Hatakeyama; T. Okamoto; Hayato Yamamoto; Atsushi Imai; T. Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama


European Urology Supplements | 2014

400 Aortic calcification index (ACI) of the patients with primary aldosteronism (PA) is an independent predictor of hypertensive status at 1 year after laparoscopic adrenalectomy (LA)

Hayato Yamamoto; H. Murasawa; Noriko Tokui; T. Okamoto; Kengo Imanishi; Y. Tobisawa; T. Yoneyama; Atsushi Imai; S. Hatakeyama; Kazuyuki Mori; Yasuhiro Hashimoto; Takuya Koie; Y. Terayama; T. Nigawara; Chikara Ohyama


European Urology Supplements | 2014

310 Glycan modification of surface glycoproteins on prostate cancer induces secretion of growth factors via enhanced interaction with prostate stromal cells

Y. Tobisawa; S. Hatakeyama; T. Okamoto; T. Yoneyama; Kazuyuki Mori; Hayato Yamamoto; Atsushi Imai; A. Okamoto; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama


European Urology Supplements | 2014

211 Immunohistochemical detection of core2 ß-1,6-N-acetylglucosaminyltransferase is an independent risk factor for PSA recurrence after radical prostatectomy

Y. Tobisawa; S. Hatakeyama; T. Yoneyama; T. Okamoto; Kazuyuki Mori; A. Okamoto; H. Murasawa; Atsushi Imai; Hayato Yamamoto; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama


European Urology Supplements | 2014

845 Glycosylation of MUC1 expressing on prostate cancer cell has crucial impact on susceptibility to natural killer cell immunity in TRAIL dependent manner

T. Okamoto; Y. Tobisawa; T. Yoneyama; Hayato Yamamoto; S. Hatakeyama; Atsushi Imai; A. Okamoto; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama; Shigeru Tsuboi


European Urology Supplements | 2013

602 Blood group antigen-targeting peptide suppresses anti-blood group antibody binding to antigen in renal glomerular capillaries after ABO-incompatible blood reperfusion

T. Yoneyama; S. Hatakeyama; Y. Tobisawa; Hayato Yamamoto; Kengo Imanishi; T. Okamoto; Noriko Tokui; N. Sugiyama; Y. Suzuki; S. Kudo; Yasuhiro Hashimoto; Takuya Koie; N. Kamimura; M. Fukuda; Chikara Ohyama


European Urology Supplements | 2013

1042 Detection of prostate cancer associated α2,3 sialyated free PSA in serum is more higher specificity than conventional PSA test

T. Yoneyama; Y. Tobisawa; Kazuyuki Mori; S. Hatakeyama; Hayato Yamamoto; T. Okamoto; A. Okamoto; F. Ishimura; Takuya Koie; N. Kamimura; Chikara Ohyama


European Urology Supplements | 2012

867 Neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer: A propensity score analysis

Takuya Koie; T. Okamoto; Y. Suzuki; Y. Tobisawa; T. Yoneyama; Kazuyuki Mori; Hayato Yamamoto; S. Hatakeyama; S. Kudoh; N. Kamimura; Chikara Ohyama

Collaboration


Dive into the T. Okamoto's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge